CEL-SCI Corporation Announces Closing Of Public Stock Offering

CEL-SCI Corporation (NYSE MKT: CVM), a late-stage oncology company, today announced the closing of its previously announced underwritten public offering. The gross proceeds to CEL-SCI from this offering were $17,826,087, prior to deducting underwriting discounts and commissions and offering expenses of the Company. The net proceeds to CEL-SCI from this offering are approximately $16,400,000 and have been received by the Company.

Chardan Capital Markets is acting as sole bookrunner for the offering and Laidlaw & Company (UK) Ltd. is acting as co-manager on the deal.

About CEL-SCI Corporation

CEL-SCI is dedicated to research and development directed at improving the treatment of cancer and other diseases by utilizing the immune system, the body's natural defense system. The lead investigational therapy is Multikine (Leukocyte Interleukin, Injection), currently being studied in a pivotal global Phase III clinical trial. CEL-SCI is also investigating a different peptide-based immunotherapy (LEAPS-H1N1-DC) as a possible treatment for H1N1 hospitalized patients and a vaccine (CEL-2000) for Rheumatoid Arthritis (currently in preclinical testing) using its LEAPS technology platform. The investigational immunotherapy LEAPS-H1N1-DC treatment involves non-changing regions of H1N1 Pandemic Flu (See Journal of Clinical Investigation – J Clin Invest. 2013; 123(7):2850-2861. doi: 10.1172/JCI67550) Avian Flu (H5N1), and the Spanish Flu, as CEL-SCI scientists are very concerned about the possible emergence of a new more virulent hybrid virus through the combination of H1N1 and Avian Flu, or maybe Spanish Flu. The Company has operations in Vienna, Virginia, and in/near Baltimore, Maryland.

Multikine is the trademark that CEL-SCI has registered for this investigational therapy, and this proprietary name is subject to FDA review in connection with its future anticipated regulatory submission for approval.

When used in this release, the words "intends," "believes," "anticipated" and "expects" and similar expressions are intended to identify forward-looking statements. Such statements are subject to risks and uncertainties which could cause actual results to differ materially from those projected. Factors that could cause or contribute to such differences include, an inability to duplicate the clinical results demonstrated in clinical studies, timely development of any potential products that can be shown to be safe and effective, receiving necessary regulatory approvals, difficulties in manufacturing any of the Company's potential products, inability to raise the necessary capital and the risk factors set forth from time to time in CEL-SCI Corporation's SEC filings, including but not limited to its report on Form 10-K for the year ended September 30, 2012. The Company undertakes no obligation to publicly release the result of any revision to these forward-looking statements which may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

Copyright Business Wire 2010

If you liked this article you might like

Biotech movers: CEL-SCI Leaps After FDA Lets Cancer Study Move Forward

A Neurotrope Stock Promotion Scheme Is Underway, but Who's Paying for It?

What Adam Feuerstein Got Right and Wrong About Biotech Stocks in 2016

4 Stocks Under $10 Making Big Moves Higher

Cel-Sci's Enrollment Math Doesn't Add up